Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022005979 - HUMANIZED ANTI-EMAP II THERAPEUTIC ANTIBODIES

Publication Number WO/2022/005979
Publication Date 06.01.2022
International Application No. PCT/US2021/039389
International Filing Date 28.06.2021
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/09 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • ALLINAIRE THERAPEUTICS, LLC [US]/[US]
Inventors
  • HAY, Douglas W.P.
  • BEREZOVSKY, Suzanne E.
  • KNIGHT, David
  • HUANG, Kexin
  • WANG, Jordon K.
Agents
  • CROTTY, Justin
  • SILVA, Domingos J.
  • BEHROOZ, Alireza
  • YOUNG, Jacque C.
  • DOYLE, Kathryn
  • BROWNING, Elizabeth
  • LANDRY, Brian
  • LEICHT, Paul
  • OSTROVSKY, Dennis
  • SIMPSON, Mark D.
  • O'SHEA MURRAY, Valerie
Priority Data
63/045,68729.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HUMANIZED ANTI-EMAP II THERAPEUTIC ANTIBODIES
(FR) ANTICORPS THÉRAPEUTIQUES ANTI-EMAP II HUMANISÉS
Abstract
(EN) The present disclosure provides monoclonal antibodies that bind to endothelial monocyte activating polypeptide II and methods of treatment using the same.
(FR) La présente invention concerne des anticorps monoclonaux qui se lient au polypeptide activant les monocytes endothéliaux II et des méthodes d'utilisation desdits anticorps.
Latest bibliographic data on file with the International Bureau